Évaluation de l’efficacité et la toxicité du protocole r-chop dans le traitement du lymphome non hodgkinien

Abstract

Non-Hodgkin's lymphomas (NHL) include lymphoid tumor diseases, apart from Hodgkin's disease, affecting lymphoid organs, especially lymph nodes, but also non-lymphoid organs. Several classifications exist, but in practice, we individualize aggressive NHL, including diffuse large B-cell lymphoma (DLBCL), which is the most common lymphoma, and indolent NHL, including follicular lymphoma and lymphoma of the mucous membrane-associated lymphoid tissue (MALT .( Curative treatment must begin as soon as the diagnosis is made. The R-CHOP protocol, which combines rituximab (an anti-CD20 monoclonal antibody) with CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone), is considered the standard first-line treatment. It is administered on one day every 3 weeks for 6 to 8 cycles. Our retro-prospective study conducted in 30 patients with diagnosed NHL, treated with the RCHOP protocol, administered intravenously, during the period from September 2019 to April 2022 at the hematology services of the anti-cancer center of Setif. The average age of our patients is 56 years with a sex ratio (M/F) of 1.14 in favor of men. The majority of patients had stage II NHL. Our results indicate that the R-CHOP protocol is well tolerated in patients and that it has brought a benefit in terms of efficacy and short-term survival, various hematological toxicities have been observed including neutropenia and anemia, and extra-hematological toxicities of which gastrointestinal toxicity is the most frequent. In the efficacy we did not find a significant correlation between age, sex and stage but we did find a significant result in relation to the type of NHL .